Nov 23 (Reuters) - Cephalon Inc:
* Ception Therapeutics and Cephalon provide initial results of a phase IIb/III
study of Cinquil in pediatric eosinophilic esophagitis
* Says Cinquil showed a statistically significant reduction in esophageal
eosinophil levels versus placebo
* Patients treated with Cinquil showed statistically significant reduction in
esophageal eosinophil levels versus placebo
* Says second co-primary endpoint, patients treated with Cinquil showed an
improvement in their clinical symptoms
* Says placebo treated patients also experienced an unexpectedly large
improvement in their symptoms
* Says there were no statistically significant differences between active
groups and the placebo group for this endpoint
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Ception Therapeutics and Cephalon provide initial results of a phase IIb/III
study of Cinquil in pediatric eosinophilic esophagitis
* Says Cinquil showed a statistically significant reduction in esophageal
eosinophil levels versus placebo
* Patients treated with Cinquil showed statistically significant reduction in
esophageal eosinophil levels versus placebo
* Says second co-primary endpoint, patients treated with Cinquil showed an
improvement in their clinical symptoms
* Says placebo treated patients also experienced an unexpectedly large
improvement in their symptoms
* Says there were no statistically significant differences between active
groups and the placebo group for this endpoint
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
